Dextech Medical AB (NGM:DEX)

Market Cap	77.27M
Revenue (ttm)	4.24M
Net Income (ttm)	-4.63M
Shares Out	18.49M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,100
Average Volume	8,881
Open	4.400
Previous Close	4.380
Day's Range	4.180 - 4.400
52-Week Range	3.540 - 6.350
Beta	1.17
RSI	51.18
Earnings Date	Apr 29, 2025

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer. Its principal product candidate is OsteoDex that has completed phase IIb clinical trial for the treatment of skeletal metastases in castration resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, to treat acromegaly, neuroendocrine ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 1
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: DEX

Financial Performance

In 2024, Dextech Medical AB's revenue was 5.39 million, a decrease of -38.18% compared to the previous year's 8.71 million. Losses were -4.71 million, 2.51% more than in 2023.